Overview

Atezolizumab for Idiopathic Pulmonary Fibrosis

Status:
Not yet recruiting

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).

Phase:

Phase 1

Details

Lead Sponsor:

Cedars-Sinai Medical Center

Collaborator:

Genentech, Inc.

Treatments:

Atezolizumab